These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 3037800)

  • 1. [Indices of the immune status of recurrent herpes patients being treated with a herpes polyvaccine].
    Belokrinitskiĭ DV; Karpovich LG; Barinskiĭ IF; Bukovskaia SN; Semenova TB
    Vopr Virusol; 1987; 32(2):229-33. PubMed ID: 3037800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Indices of lymphocyte functional activity in patients with recurrent cutaneous-genital herpes during treatment with a herpes vaccine].
    Karpovich LG; Blokha VV; Kalashnikova TV; Bychkova AA; Semenova TB
    Vopr Virusol; 1986; 31(2):200-5. PubMed ID: 3014750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Dynamics of cellular immunity indices in patients with ophthalmic herpes treated with a herpetic polyvaccine].
    Barinskiĭ IF; Blokha VV; Bukovskaia SN; Belokrinitskiĭ DV; Belkina IV
    Vopr Virusol; 1988; 33(2):212-7. PubMed ID: 2842963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Vaccine and poludan in experimental and clinical herpes simplex].
    Semenova TB; Selezneva AIu; Fadeeva LL; Barinskiĭ IF
    Vestn Dermatol Venerol; 1984 Nov; (11):24-7. PubMed ID: 6099018
    [No Abstract]   [Full Text] [Related]  

  • 5. Seventeen years of application of herpes vaccines in Bulgaria.
    Dundarov S; Andonov P
    Acta Virol; 1994 Aug; 38(4):205-8. PubMed ID: 7879710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Indices of alpha-interferon and of lymphocyte natural killer activity in genital herpes and the effect on them of specific vaccinal therapy and interferon therapy].
    Barinskiĭ IF; Popova OM; Konstantinova IV; Grebeniuk VN; Kuznetsov VP
    Vopr Virusol; 1985; 30(3):340-3. PubMed ID: 2996242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Experience with the combined treatment of recurrent herpes using larifan and a herpetic vaccine].
    Potekaev NS; Nosik NN; Samgin MA; Kudratullaev KN; Lavrukhina LA
    Klin Med (Mosk); 1992 Jan; 70(1):67-70. PubMed ID: 1318984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Herpes vaccines].
    Novitskiĭ VA; Pushkarskaia NL; Barinskiĭ IF
    Vopr Virusol; 1987; 32(3):261-77. PubMed ID: 2823480
    [No Abstract]   [Full Text] [Related]  

  • 9. Immunotherapy with inactivated polyvalent herpes vaccines.
    Dundarov S; Andonov P; Bakalov B; Nechev K; Tomov C
    Dev Biol Stand; 1982; 52():351-8. PubMed ID: 6299844
    [No Abstract]   [Full Text] [Related]  

  • 10. [Protective effect of a commercial vaccine, poludan and their combinations in an experimental herpes infection].
    Khaletskaia EV; Fadeeva LL; Selezneva AIu; Semenova TB
    Zh Mikrobiol Epidemiol Immunobiol; 1987 Feb; (2):51-4. PubMed ID: 2437741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Mechanisms for the therapeutic effect of herpes polyvaccines in chronic ophthalmic herpes and genital herpes].
    Barinskiĭ IF; Karpovich LG; Gubanova EI; Belkina IV; Semenova TB; Lazarenko AA; Davydova AA; Samoĭlenko II; Kasparov AA
    Vopr Virusol; 2000; 45(1):30-3. PubMed ID: 10695041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Specific immunotherapy of recurrent genital herpes].
    Grebeniuk VN
    Vestn Dermatol Venerol; 1983 Nov; (11):12-4. PubMed ID: 6322468
    [No Abstract]   [Full Text] [Related]  

  • 13. [Specific immunostimulation in the therapy of recurrent herpes simplex type I or II].
    Veneroni G; Calixte C; Bozzo Costa E; Germogli R
    Boll Ist Sieroter Milan; 1987; 66(6):427-34. PubMed ID: 2839208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Antiherpetic cultural inactivated divaccine (experience in its preparation and study of its therapeutic effectiveness)].
    Bikbulatov RM; Demidova SA; Alekseeva AA; Cheglakov IuA; Kozlova VI
    Sov Med; 1983; (3):50-4. PubMed ID: 6304919
    [No Abstract]   [Full Text] [Related]  

  • 15. [Clinico-immunological aspects of recurrent herpes simplex during vaccine therapy].
    Semenova TB; Karpovich LG; Barinskiĭ IF; Blokha VV; Kalashnikova TV
    Vestn Dermatol Venerol; 1988; (7):49-53. PubMed ID: 2851233
    [No Abstract]   [Full Text] [Related]  

  • 16. Immunogenicity and protective efficacy in a rhesus monkey model of vaccine Ac NFUi(S-) MRC against primary type 2 herpes simplex virus infection.
    Skinner GR; Buchan A; Williams D; Marsden J; Hartley C; Wilbanks G; Turyk M; Namkoong ES
    Br J Exp Pathol; 1982 Aug; 63(4):378-87. PubMed ID: 6295430
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neonatal herpes simplex virus infection: relapse after initial therapy and transmission from a mother with an asymptomatic genital herpes infection and erythema multiforme.
    Brown ZA; Ashley R; Douglas J; Keilly M; Corey L
    Pediatr Infect Dis J; 1987 Nov; 6(11):1057-61. PubMed ID: 2827097
    [No Abstract]   [Full Text] [Related]  

  • 18. Herpes simplex virus vaccines.
    Meignier B; Roizman B
    Antiviral Res; 1985; Suppl 1():259-65. PubMed ID: 3002260
    [No Abstract]   [Full Text] [Related]  

  • 19. [Short-term therapeutic effect of an inactivated herpes simplex virus type 1 vaccine on herpes simplex keratitis].
    Zhang YQ
    Zhonghua Yan Ke Za Zhi; 1983 Nov; 19(6):339-42. PubMed ID: 6327206
    [No Abstract]   [Full Text] [Related]  

  • 20. Genital herpes.
    Oates JK
    Br J Hosp Med; 1983 Jan; 29(1):13-22. PubMed ID: 6297643
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.